BACKGROUND: We investigated the reasons for switching antiretroviral regimens, an issue rarely addressed in cohort studies. METHODS: An observed toxicity switch rate (OTSR) was calculated by Poisson regression using the number of days individuals received each individual antiretroviral drug. RESULTS: Of 3333 individuals receiving HAART, a total of 14% of regimens were switched, the majority occurring after 6 months of therapy. Toxicity was the major reason for switching (61%) and there were no major statistically significant differences in OTSR between the protease inhibitor (OTSR 26.4, 95% CI 18.3-37) and non-nucleoside reverse transcriptase inhibitor (OTSR 22.2, 95% CI 13.6-34.4) based regimes. For individual antiretrovirals, stavudine and zidovudine had significantly higher "switch" scores than all other drugs. CONCLUSIONS: There were no differences between the major HAART classes in OTSR. We suggest that newer antiretrovirals will require differentiation in terms of longer-term toxicity, as this is the major reason for switching.
BACKGROUND: We investigated the reasons for switching antiretroviral regimens, an issue rarely addressed in cohort studies. METHODS: An observed toxicity switch rate (OTSR) was calculated by Poisson regression using the number of days individuals received each individual antiretroviral drug. RESULTS: Of 3333 individuals receiving HAART, a total of 14% of regimens were switched, the majority occurring after 6 months of therapy. Toxicity was the major reason for switching (61%) and there were no major statistically significant differences in OTSR between the protease inhibitor (OTSR 26.4, 95% CI 18.3-37) and non-nucleoside reverse transcriptase inhibitor (OTSR 22.2, 95% CI 13.6-34.4) based regimes. For individual antiretrovirals, stavudine and zidovudine had significantly higher "switch" scores than all other drugs. CONCLUSIONS: There were no differences between the major HAART classes in OTSR. We suggest that newer antiretrovirals will require differentiation in terms of longer-term toxicity, as this is the major reason for switching.
Authors: Christa R Nevin; Jiatao Ye; Inmaculada Aban; Michael J Mugavero; David Jackson; Hui-Yi Lin; Jeroan Allison; James L Raper; Michael S Saag; James H Willig Journal: AIDS Res Hum Retroviruses Date: 2011-03-21 Impact factor: 2.205
Authors: Sowmyanarayanan V Thuppal; Christine A Wanke; Farzad Noubary; Joshua T Cohen; Mkaya Mwamburi; Abraham C Ooriapdickal; Jayaprakash Muliyil; Gagandeep Kang; George M Varghese; Priscilla Rupali; Rajiv Karthik; Rajkumar Sathasivam; Peace Clarance; Susanne A Pulimood; Dincy Peter; Leni George Journal: Trans R Soc Trop Med Hyg Date: 2015-03-15 Impact factor: 2.184
Authors: Hamish McManus; Jennifer F Hoy; Ian Woolley; Mark A Boyd; Mark D Kelly; Brian Mulhall; Norman J Roth; Kathy Petoumenos; Matthew G Law Journal: Antivir Ther Date: 2014-04-04
Authors: Matthias Stoll; Christian Kollan; Frank Bergmann; Johannes Bogner; Gerd Faetkenheuer; Carlos Fritzsche; Kirsten Hoeper; Heinz-August Horst; Jan van Lunzen; Andreas Plettenberg; Stefan Reuter; Jürgen Rockstroh; Hans-Jürgen Stellbrink; Osamah Hamouda; Barbara Bartmeyer Journal: PLoS One Date: 2011-09-09 Impact factor: 3.240
Authors: Richard de Boer; Ruben L Smith; Winnok H De Vos; Erik M M Manders; Stanley Brul; Hans van der Spek Journal: PLoS One Date: 2015-05-13 Impact factor: 3.240
Authors: Christine Njuguna; Catherine Orrell; Richard Kaplan; Linda-Gail Bekker; Robin Wood; Stephen D Lawn Journal: PLoS One Date: 2013-05-22 Impact factor: 3.240